The 20 Best Diffuse Large B-Cell Lymphoma (DLBCL) Doctors Near Me in Ann Arbor, MI

Monalisa Ghosh, MD, Assistant Professor. Dr. Ghosh graduated with honors from the University of Alabama at Birmingham with a BS in Biomedical Engineering, minor in Mathematics and Chemistry. She earned her MD from the University of Alabama School of Medicine where she also completed her residency training. Her fellowship training was completed at the NIH/NCI Medical Oncology Fellowship Program. Dr. Ghosh’s research interest is in bone marrow trans-plantation and cellular therapies to treat lymphoma. Dr. Ghosh will be seeing patients on the BMT service. Dr. Ghosh is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). She is also highly rated in 27 other conditions, according to our data. Her clinical expertise encompasses Follicular Lymphoma, Graft Versus Host Disease (GvHD), Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Colonoscopy.

Dr. Karimi is an Clinical Assistant Professor of Medicine in the Division of Hematology/Oncology at the University of Michigan. Dr. Karimi received her undergraduate degree from Johns Hopkins University, her medical degree from the University of Pennsylvania School of Medicine and went on to complete her internal medicine residency and chief residency at the University of Chicago. She completed her Hematology & Oncology fellowship at Stanford University before joining the lymphoma group at the University of Michigan Rogel Cancer Center.Her research focus is on conducting clinical trials in B cell lymphomas including diffuse large B cell lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, Hodgkin's lymphoma and CLL/SLL. Dr. Karimi is a member of the Non-Hodgkin Lymphoma Guidelines panel for the National Comprehensive Cancer Center Network (NCCN).Dr. Karimi finds joy in connecting with patients and families and is honored to be a part of their care team in their cancer journey. She has personal experience knowing how challenging it can be to navigate the decisions and treatments of indolent and aggressive lymphomas. Her goal is to provide meticulous and compassionate patient care while incorporating the most up to date understanding of the disease and latest advances in treatments to each patient's case.Outside of the hospital, Dr. Karimi enjoys cooking, yoga, and hiking in the national parks across America. Languages spoken: English, Spanish, Urdu, Gujarati. Dr. Karimi is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). She is also highly rated in 20 other conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), and Bone Marrow Aspiration. Dr. Karimi is board certified in Internal Medicine, Hematology, and Medical Oncology.

Dr. Carty completed her undergraduate work at Harvard University, graduating magna cum laude, with a degree in Biochemical Sciences. She attended the Albert Einstein College of Medicine in New York where she earned her MD degree. Dr. Carty stayed in New York for her internal medicine residency at Columbia University Medical Center, and moved to the Hospital of the University of Pennsylvania for her Hematology-Oncology fellowship. She remained on staff at the Hospital of the University of Pennsylvania before moving here to Ann Arbor. Dr. Carty is the recipient of a K08 Award for her work in T cell biology and ASH Scholar Award for her research on T cell lymphomas. Dr. Carty is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). She is also highly rated in 21 other conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Large-Cell Immunoblastic Lymphoma, and Bone Marrow Aspiration. Dr. Carty is board certified in Hematology.

Dr. Lauren Smith received her undergraduate degree at the University of Michigan Honors College with highest distinction in 1992. She spent four years working in a neurogenetics laboratory at the University of San Francisco with Dr. Nelson Freimer. For the next two years she worked as a manuscript editor for Dr. Donald Klein, a psychiatrist, at Columbia University. In 1998, she began medical school at the University of Michigan. She was awarded AOA in her junior year and was president of the UM AOA Chapter the following year. She completed her residency in anatomic/clinical pathology and fellowship in hematopathology from 2002-2007. In July, 2007 she began her faculty career as an Assistant Professor at the University of Michigan and was promoted to Associate Professor in 2013. She was appointed Fellowship Director in 2013. She was appointed the Director of the Ethics Path of Excellence in the University of Michigan Medical School in 2013. She became the permanent Director of the Hematopathology Section in 2016. In addition, she serves as a Hospital Ethicist at UMHS. Dr. Smith is rated as an Advanced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). She is also highly rated in 29 other conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, T-Cell Lymphoma, Peripheral T-Cell Lymphoma, and Angioimmunoblastic T-cell Lymphoma.

Mark Kaminski is an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Kaminski is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Gastric Lymphoma, and Bone Marrow Aspiration.

Attaphol Pawarode is a Hematologist and an Internal Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Pawarode is rated as an Advanced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Burke joined the faculty in July 2014. He attended Providence College in Rhode Island where he earned his BS in Biology. Subsequently, he matriculated at the Icahn School of Medicine at Mount Sinai and earned his MD. He then completed a residency in Internal Medicine at the University of Chicago Medical Center, followed by a year serving as a Chief Resident. He recently completed his Hematology/Medical Oncology fellowship at Memorial Sloan Kettering Cancer Center in New York where his clinical and research interests focused on leukemia, particularly adult acute lymphoblastic leukemia (ALL). He performed clinical research regarding the role of asparaginase and “pediatric-inspired” therapeutic regimens in adult ALL, as well as investigating therapies that spare cytotoxic chemotherapy in older adult Philadelphia chromosome-positive ALL. Dr. Burke is focused on early phase clinical trials in acute leukemias and is treating patients with hematologic malignancies. Dr. Burke is rated as an Advanced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Aplastic Anemia, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Burke is board certified in Hematology and Medical Oncology.

John Maciejewski is a Hematologist and an Internal Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Maciejewski is rated as an Advanced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Multiple Myeloma, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

The T-cell lymphomas are a heterogeneous and poorly understood group of non-Hodgkin’s lymphomas. The most common T-cell lymphoma in the United States includes a heterogeneous mix of lymphomas that lack distinguishing characteristics and, until recently, remained clinically and molecularly “unspecified”. Improved understanding of T-cell lymphoma pathogenesis and the development of novel therapeutic strategies will be needed to address this challenge and improve outcomes for patients afflicted with these aggressive lymphomas. My group made the landmark discovery that the most common T-cell lymphoma in North America is comprised of two molecularly and clinically distinct subsets. This finding has significant implications for the classification and treatment of these lymphomas. We have also demonstrated that malignant T cells remain dependent upon antigen-presenting cells within the tumor microenvironment and are developing novel therapeutic strategies targeting these cells. Many fundamental questions, including the “cell of origin”, the role of antigen-, costimulatory-, and cytokine-receptor signaling, and the contribution of myeloid-derived antigen-presenting cells in disease pathogenesis remain obscure. My laboratory uses complementary mouse models and primary T-cell lymphoma specimens (in ex vivo and patient-derived xenograft studies) to address these fundamental and clinically relevant questions. We are poised to clinically translate our laboratory-based findings into novel therapeutic strategies that we hope will improve outcomes for patients afflicted with these aggressive lymphomas. I enjoy working with a multidisciplinary team of enthusiastic collaborators who share this common goal. Dr. Wilcox is rated as an Advanced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Wilcox is board certified in Internal Medicine, Hematology, and Medical Oncology.

I ride both a road bike and Peleton. I golf about 2-3 times per week. Have four grandchildren to dote on. I mostly fiction novels. Exercise twice per week. Dr. Terebelo is rated as an Advanced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). He is also highly rated in 62 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Essential Thrombocythemia, Familial Colorectal Cancer, Bone Marrow Aspiration, and Tissue Biopsy.

Darren King is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. He has been practicing medicine for over 18 years. Dr. King is rated as an Advanced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. King is board certified in Hematology and Medical Oncology.

Sarah Anand is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Anand is rated as an Experienced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Colonoscopy. Dr. Anand is board certified in Internal Medicine, Hematology, and Medical Oncology.

Dr. Dale Bixby has been practicing hematology at the University of Michigan since 2009. He obtained his PhD in Medicinal Chemistry and Pharmaceutics at the University of Kentucky in 1999, before beginning his medical training at the University of Michigan in Ann Arbor, MI. He was a resident in the Department of Internal Medicine and then completed fellowship training in hematology and medical oncology at the University of Michigan. Dr. Bixby is currently a clinical professor and specializes in the areas of myeloid and lymphoid leukemias, myelodysplastic syndrome and bone marrow failure disorders. Dr. Bixby currently serves as the section chief of the acute leukemia program. He is also a clinical investigator in hematological malignancies. Dr. Bixby is rated as an Experienced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). He is also highly rated in 34 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia (CML), and Bone Marrow Aspiration. Dr. Bixby is board certified in Hematology.

Dr. Magenau is currently an Assistant Professor at the University of Michigan and the Adult Clinical BMT director of the Blood and Marrow Transplantation Program. He holds a Bachelor of Science in Biology from Pennsylvania State University, and obtained his M.D. from the Temple University in Philadelphia, Pennsylvania. Dr. Magenau then trained in internal medicine at the University of Illinois in Chicago.Dr. Magenau is the lead clinical investigator on several trials including experience in clinical HCT, responsible research practices, team science, and conducting multicenter prospective HCT clinical trials in high risk populations (Acute Myeloid Leukemia not in remission at time of HCT). He also has a background in developing, performing, and monitoring HCT studies that integrate immune analysis of human samples. Dr. Magenau is rated as an Experienced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Multiple Myeloma, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Magenau is board certified in Hematology.

Marcus Geer is a Hematologist and an Internal Medicine provider practicing medicine in Ann Arbor, Michigan. He has been practicing medicine for over 10 years. Dr. Geer is rated as an Experienced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Graft Versus Host Disease (GvHD), Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Transplant. Dr. Geer is board certified in Internal Medicine, Medical Oncology, and Hematology.

Mary Riwes is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Riwes is rated as an Experienced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Colonoscopy.

Dr. Pettit studied physics and magazine journalism at Syracuse University prior to earning her MD from the Chicago Medical School. She went on to complete her residency in internal medicine and fellowships in hematology/oncology and clinical pharmacology/pharmacogenomics at the University of Chicago. She has received national recognition for her research, including the Conquer Cancer Foundation/ASCO Young Investigator Award, the ASCPT Presidential Trainee Award, and selection for the ASH Clinical Research Training Institute. Dr. Pettit focuses on translational research and drug development for patients with myeloid malignancies, specifically myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia. Dr. Pettit is rated as an Experienced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). She is also highly rated in 30 other conditions, according to our data. Her clinical expertise encompasses Myelofibrosis, Myeloproliferative Neoplasms (MPN), Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Splenectomy. Dr. Pettit is board certified in Medical Oncology and Hematology.

Erica Campagnaro is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Campagnaro is rated as an Experienced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). She is also highly rated in 27 other conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Campagnaro is board certified in Internal Medicine and Hematology.

Dr. Cusick pursued her undergraduate studies at Knox College in Galesburg, IL. She attended the University of Iowa School of Medicine where she earned her MD. Dr. Cusick completed her residency training in Internal Medicine at the University of Wisconsin Hospital and Clinics where she also completed a Hematology Fellowship. Dr. Cusick joined the faculty of Hematology/Oncology from Geisinger Medical Center’s Department of Hematology and Oncology in Danville, PA. Dr. Cusick is rated as an Experienced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). She is also highly rated in 7 other conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Hypereosinophilic Syndrome, Acute Eosinophilic Pneumonia, Adult Immune Thrombocytopenia, and Bone Marrow Aspiration. Dr. Cusick is board certified in Hematology.

Jonathan Weiss is a Hematologist and an Internal Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Weiss is rated as an Experienced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Gastric Lymphoma, Hodgkin Lymphoma, and Mantle Cell Lymphoma (MCL).